But that is exactly what share prices of other early stage developer stocks made to shoot up. Efficacy proven by lab tests announced ==> BANG !!!
Here we are seeking excuses again, as to why it does not happen for GNBT.
Maybe not everybody has understood the PR, which I actually find much better written than the once written in recent history! It much better explains what they have achieved.
Maybe a lot of investors think "not another early stage vaccine manufacturer, we already have several approved. What the heck!"
I still think that they have made a much better job to explain why this vaccine is still needed.
What I actually think that they should've have put more emphazise on, is the therapeutic topic that mentioned only in a few short lines at the end.
Other than that, I am actually quiet happy with that PR. Jeannie is out of the bottle, now we just need to ask her to have the appropriate effect on the share price.
Here we are seeking excuses again, as to why it does not happen for GNBT.
Maybe not everybody has understood the PR, which I actually find much better written than the once written in recent history! It much better explains what they have achieved.
Maybe a lot of investors think "not another early stage vaccine manufacturer, we already have several approved. What the heck!"
I still think that they have made a much better job to explain why this vaccine is still needed.
What I actually think that they should've have put more emphazise on, is the therapeutic topic that mentioned only in a few short lines at the end.
Other than that, I am actually quiet happy with that PR. Jeannie is out of the bottle, now we just need to ask her to have the appropriate effect on the share price.
3
